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The utility value was compared among 3 surgical interventions,  and the validity of the time trade-oﬀ 
(TTO) method was evaluated by analyzing the correlations of the utility value with the results of the 
Visual Function Questionnaire-14 (VF-14) and other variables.  The subjects were 127 patients aged 
40-85 years who were surgically treated between January 2008 and March 2010,  including 26 patients 
with glaucoma,  50 with cataracts,  and 51 with comitant strabismus.  The scores on VF-14 and utility 
values determined using TTO were calculated retrospectively.  The mean value (SD) of the utility gain 
was 0.096 (0.105) for glaucoma,  0.101 (0.105) for comitant strabismus,  and 0.167 (0.237) for unilateral 
and 0.245 (0.167) for bilateral cataracts,  indicating signiﬁcant postoperative improvements in the utility 
value.  A signiﬁcant correlation was observed between the utility value and the postoperative VF-14 
scores of the bilateral cataracts,  and the postoperative visual acuity of the better eye of the unilateral 
cataract.  The mean value of the quality-adjusted life years was 2.181 for bilateral and 1.424 for unilat-
eral cataracts,  1.132 for strabismus,  and 0.870 for glaucoma with an annual discount rate of 3ｵ.  The 
gain of utility value was highest in bilateral cataracts,  and lowest in glaucoma,  and thus the TTO 
analysis was considered to be highly valid for cataract surgery.
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tility analysis is a generic instrument,  applica-
ble across interventions in all specialties,  which 
quantiﬁes the QOL associated with a health state [1].  
The utility value used in utility analysis is an index of 
the severity of diseases deﬁned on a continuous scale 
from 0 to 1,  where 0 corresponds to the worst possi-
ble QOL weight,  equal to death,  and 1 corresponds to 
the best possible QOL weight,  equal to perfect health.  
There are 4 basic variants of utility analysis,  time 
trade-oﬀ (TTO),  standard gamble,  willingness to pay,  
and multi-attribute.  Of these,  TTO utility analysis is 
the most appropriate and is an instrument that is 
understood by the majority of patients [2-6] and 
shows good reproducibility [7-10].  The validity of the 
TTO analysis is demonstrated by the fact that when 
visual acuity in the better-seeing eye decreases,  the 
TTO utility decreases correspondingly [9,  11].
　 Using the utility value,  the quality-adjusted life 
years (QALYs) can be calculated [2,  12].  QALYs 
are calculated by multiplying the measured mean util-
ity gain by the measured mean life expectancy,  and can 
be used as a unit for evaluating the eﬀect of medical 
intervention.  By dividing the actual medical expendi-
ture by the QALYs,  the eﬃciency of medical inter-
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vention,  i.e.,  cost-eﬀectiveness,  can be calculated.  To 
more eﬃciently use the limited medical resources 
available today,  analysis of the cost-eﬀectiveness of 
various medical interventions is considered important 
in devising health care policies [12].  Reports [13] 
summarizing the cost-eﬀectiveness in the ﬁeld of oph-
thalmology published to date include those dealing with 
premature retinopathy,  macular edema associated with 
retinal vein branch occlusion,  laser therapy for chor-
oidal neovascular membrane associated with age-
related macular degeneration,  amblyopia treatment,  
cataract surgery,  vitrectomy for vitreous hemorrhage 
in diabetes,  and surgery for proliferative vitreoreti-
nal diabetic retinopathy.  
　 This study aimed to calculate and evaluate the util-
ity value of surgical treatment in patients with cata-
ract,  glaucoma,  and comitant strabismus,  who were 
experiencing the inconvenience of visual disorders,  
and to compare their changes using TTO analysis.  We 
evaluated the validity of TTO analysis by examining 
the correlations of the TTO utility value with the 
results of VF-14 [14],  which is a vision-speciﬁc QOL 
scale [15-20],  and visual acuity.
Materials and Methods
　 Subjects. The subjects were 222 patients aged 
40-85 years,  including 45 patients with glaucoma,  88 
with cataracts,  and 89 with comitant strabismus who 
were surgically treated at the Okayama University 
Hospital between January 2008 and March 2010.  Of 
these 222 patients,  127 patients,  including 26 with 
glaucoma,  50 with cataracts,  and 51 with comitant 
strabismus,  answered the questionnaire.  All gave 
informed consent according to a protocol conforming 
to the Declaration of Helsinki,  approved by the 
Institutional Review Board of the Okayama University 
Graduate School of Medicine,  Dentistry,  and 
Pharmaceutical Sciences.
　 Indication of surgical treatment. The sur-
gery for comitant strabismus was determined by con-
sidering the impairment of binocular function in daily 
life in addition to psychological diﬃculties such as 
physical features.  Concerning glaucoma,  patients 
showing poor control of intraocular pressure with 
drugs and those showing progression of visual ﬁeld 
loss despite adequate control of intraocular pressure 
were considered to have a surgical indication,  and 
glaucoma surgery by trabeculectomy or trabeculotomy 
was selected individually.  Glaucoma patients who 
underwent ﬁltering surgery combined with cataract 
surgery were excluded from this study.  Cataract 
surgery was evaluated by considering the living envi-
ronment as well as visual acuity,  and bilateral surgery 
was performed at an interval of 1-2 weeks.  
Phacoemulsiﬁcation,  aspiration and intraocular lens 
implantation were performed in all patients,  and uni- 
or bilateral surgery was carried out depending on the 
patientʼs condition.  Cataract cases were divided into 
2 groups,  uni- and bilateral cataract surgery.  
Strabismus cases with glaucoma or cataract surgery 
were excluded from this study.  Moreover,  glaucoma 
or cataracts cases who needed strabismus surgery 
were also excluded from this study.  
　 Measurement of the visual acuity and visual 
ﬁeld. The visual acuity was examined at a dis-
tance of 5m.  Decimal visual acuity values of less than 
0.01 were expressed by the following: Counting ﬁn-
gers was scored as 0.014,  and hand motion as 0.005 
at 30cm [21].  For statistical analyses,  decimal 
visual acuity values were converted to log MAR.  The 
visual ﬁeld was measured in each eye using a 
Humphrey Field Analyzer II (Carl Zeiss Meditec,  
USA,  SITA StandardTM).  Mean deviation (MD) 
scores were used to assess the severity of visual ﬁeld 
loss.  Severity of visual ﬁeld loss was classiﬁed into 3 
stages : MD＞－6dB for early stage,－12 dB≦MD≦
－6dB for intermediate stage,  and MD＜－12 dB for 
late stage loss [22].
　 Pre- and postoperative VF-14 scores and 
TTO measurements. A VF-14 questionnaire and 
a TTO measurement sheet were mailed to the patients 
2 to 3 months postoperatively,  and the pre- and post-
operative scores of these measures were entered.  We 
instructed patients that they must complete the ques-
tionnaire themselves,  rather than allowing a caregiver 
or other acquaintance to do so on their behalf.  The 
questionnaire consisted of the Japanese version of 
VF-14 [23],  and a questionnaire for the TTO utility 
values.  In the TTO utility analysis,  patients were told 
to assume that there was a surgical treatment that 
would oﬀer them perfect vision if successful,  and 
asked whether they would be willing to trade oﬀ some 
of their expected remaining years for perfect vision.  
The expected remaining years were based on data 
from the Japanese Ministry of Health,  Labor and 
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Welfare of 2008.  The utility value was calculated 
using the following equation: Utility value=1-time 
traded/expected remaining years.
　 Relationship of TTO and VFQ with visual 
acuity. The correlations between QOL measures 
and visual acuity were analyzed to evaluate the rela-
tionship between the 2 variables.  The pre- and post-
operative TTO utility values,  total VF-14 scores,  and 
correlation of the corrected visual acuity between the 
better and worse eyes were calculated.  
　 Relationships of the TTO utility value with 
other independent variables. To analyze the 
relationships of the TTO utility value with various 
variables,  multiple regression analysis was carried 
out.  The pre- and postoperative TTO utility values 
were used as dependent variables,  and the pre- and 
postoperative visual acuities,  age,  gender,  and VF-14 
score as independent variables.  In addition,  the MD 
score in visual ﬁeld loss was used as an independent 
variable in glaucoma,  and the size of ocular deviation 
and the binocular single vision were used as indepen-
dent variables in comitant strabismus.  
　 Calculation of QALYs. The utility gain was 
calculated from the pre- and postoperative TTO utility 
values,  and it was assumed that surgery would lead to 
no change in life expectancy.  The number of QALYs 
gained was calculated by multiplying the measured 
utility gain and the patientʼs life expectancy,  with an 
assumed annual discount rate of 3ｵ [24] recom-
mended,  by using the following discounting formula by 
Bauchamp et al.  [25]:
N
i＝1
umber of QALYs=ΔU×LE×∑
LE
1/（1＋DR)i-0.5,  
where ΔU is the measured mean utility gain,  LE is life 
expectancy and DR is discount rate.
　 Statistical analysis. The chi-square test was 
used to compare the diﬀerence in distribution in the 
clinical characteristics of the 4 treatment groups.  To 
compare the pre- and postoperative TTO utility values 
and the VF-14 score,  the t-test was used.  Pearsonʼs 
correlation coeﬃcient was used to analyze the relation 
between pre- and postoperative utility values,  and 
between the VF-14 score and visual acuity.  Multiple 
regression analysis was used to assess the coeﬃcient 
of determination using pre- and postoperative TTO 
utility values as dependent variables.  Analyses were 
done using the statistical software package JMP (ver.  
8.0; SAS Institute Inc.,  NC,  USA).
Results
　 Response rates to the questionnaire (Table 
1). There was no marked diﬀerence in response 
rates to the questionnaire among the 4 treatment 
groups: the rates were 57.3ｵ for comitant strabis-
mus,  57.8ｵ for glaucoma,  56.8ｵ for unilateral cata-
ract,  and 57.2ｵ for bilateral cataract.
　 Characteristics of the analyzed subjects 
(Table 1). The mean ages (SD) of patients with 
comitant strabismus,  glaucoma,  unilateral and bilat-
eral cataracts were 62.7 (10.8),  69.6 (11.7),  70.9 
(10.9),  and 74.5 (5.8),  respectively.  The male: female 
ratios of these patients were 25: 26,  12: 14,  14: 7,  
and 17: 12,  respectively.  The disease type of comi-
tant strabismus was exotropia in 43 (84.3ｵ) and 
esotropia in 8 patients (15.7ｵ).  The preoperative 
mean far deviation (SD) was 44.8 (18.4) prism 
diopters (pds.),  and postoperatively it was 7.8 (9.8) 
pds.,  with a mean rate of correction (SD) of 82.2ｵ 
(23.0).  Eight patients (15.7ｵ) showed binocular single 
vision at distance with the Bagolini striated glasses 
test preoperatively,  and 32 patients (62.7ｵ) did so 
postoperatively.
　 The disease type of glaucoma was primary open 
angle glaucoma in 12 (46.2ｵ),  primary angle closure 
glaucoma in 1 (3.8ｵ),  secondary with exfoliation 
glaucoma in 8 (30.8ｵ),  and other types in 5 patients 
(19.2ｵ).  The preoperative mean MD of the better eye 
was －6.9 dB,  and postoperatively it was －6.5 dB,  
with no signiﬁcant diﬀerence between the pre- and 
postoperative MD value (p=0.867,  t-test).  The preop-
erative proportion ratios of the number of patients 
classiﬁed in the 3 stage,  early,  intermediate,  and late 
stage of visual ﬁeld loss of the better eye were 
52.1ｵ,  26.1ｵ,  and 21.7ｵ,  and the corresponding 
postoperative ratios were 58.3ｵ,  16.7ｵ,  and 25.0ｵ,  
with no signiﬁcant diﬀerence between the 3 stage pre- 
and postoperative proportion rate (chi square test,  p= 
0.868).  Moreover,  we calculated the medication 
scores,  and compared the pre- and postoperative val-
ues by scoring 1 point per instillation and 2 points per 
internal medicine dose.  The percent rate of patients 
who stopped using medication increased from 0ｵ to 
36.4ｵ postoperatively.  The mean medication score 
(SD) was signiﬁcantly decreased from 3.18（0.75） 
to 0.82（0.87) postoperatively (p=0.001,  t-test).
　 Cataract was age-related in all patients,  and those 
193Time Trade-oﬀ Utility AnalysisApril 2012
with corrected visual acuity of 0.5 or less in visual 
acuity in the worse eye accounted for high percent-
ages (61.9ｵ for unilateral and 55.2ｵ for the bilateral 
cataract surgery group).
　 Results of VF-14 (Tables 1 and 2). The 
VF-14 Questionnaire was completed by 51 patients 
with comitant strabismus,  26 with glaucoma,  and 50 
with cataracts,  for a total of 127 (57.2ｵ).  The pre-
operative score was 80 or higher in a higher percent-
age of patients with glaucoma compared with the other 
3 groups,  but the postoperative score showed no dif-
ference in distribution among the 4 groups.  The mean 
(SD) of the diﬀerence between the pre- and postopera-
tive scores was 1.5 (16.1) in patients with glaucoma,  
11.5 (15.1) in those with unilateral cataracts,  13.5 
(16.0) in those with strabismus,  and 17.0 (21.3) in 
those with bilateral cataracts (Fig.  1).  The score 
improved signiﬁcantly after surgery in the comitant 
strabismus (p＜0.0001,  t-test),  unilateral cataract (p
＜0.0002) and bilateral cataracts groups (p=0.0002),  
but not in the glaucoma group (p=0.6407).
　 Results of TTO utility analysis (Tables 1 and 
2). The TTO questionnaire was completed by 47 
patients with comitant strabismus,  26 with glaucoma,  
and 44 with cataracts,  for a total of 117 respondents 
(52.7ｵ).  No signiﬁcant diﬀerence was noted in the 
distribution of utility values among the 4 groups 
before and after surgery (p=0.1883,  chi square test,  
for pre-,  and p=0.5986 for postoperatively).  Fig.  2 
shows the means (SD) of the pre- and postoperative 
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Table 1　 Preoperative clinical characteristics
Comitant  
strabismus
Glaucoma Unilateral  
cataract
Bilateral  
cataract
P
Enrolled patients 89   　　 45   　　 37 　　 51 　　
　Responder 51   　　 26   　　 21   　　 29   　　
Gender, Number 0.3411
　Male 25　(49%) 12　(46%) 14　(67%) 17　(59%)
　Female 26　(51%) 14　(54%) 7　(33%) 12　(41%)
Age, yrs. 0.4252
　Mean (SD) 62.7 (10.8) 69.6 (11.7) 70.9 (10.9) 74.5　(5.8)
　≥80 3　 (6%) 6　(23%) 5　(24%) 6　(21%)
　60≤　<80 28　(55%) 16　(62%) 12　(57%) 22　(76%)
　40≤　<60 20　(39%) 4　(15%) 4　(19%) 1 　(3%)
VA in better eye 0.2922
　Mean (SD), decimal 1.2　(0.3) 1.0　(0.3) 0.9　(0.5) 0.7　(0.3)
　≥1.0 46　(90%) 17　(65%) 11　(52%) 8　(28%)
　0.5≤　<1.0 3　 (6%) 7　(27%) 5　(24%) 14　(48%)
　<0.5 2　 (4%) 2　 (8%) 5　(24%) 7　(24%)
VA in worse eye 0.4083
　Mean (SD), decimal 0.9　(0.4) 0.6　(0.5) 0.3　(0.3) 0.4　(0.3)
　≥1.0 34　(67%) 8　(31%) 0   　　 1 　(3%)
　0.5≤　<1.0 9　(18%) 8　(31%) 8　(38%) 12　(41%)
　<0.5 8　(16%) 10　(38%) 13　(62%) 16　(55%)
VF-14 score 0.4252
　Mean (SD) 72.3 (21.1) 80.7 (17.5) 73.0 (15.1) 69.8 (21.5)
　Median 72.9　　 82.0　　 　70.5 　72.5
　100≥　≥80 19　(37%) 15　(58%) 6　(29%) 10　(35%)
　 80>　≥40 28　(55%) 10　(39%) 15　(72%) 17　(59%)
　 40>　≥0 4　 (8%) 1　 (4%) 0   　　 2　 (6%)
Utility value 0.1883
　Mean (SD) 0.852 (0.124) 0.810 (0.171) 0.727(0.279) 0.663 (0.196)
　1.0 12　(26%) 6　(23%) 4　(22%) 2　 (8%)
　1.0>　≥0.5 35　(74%) 19　(73%) 11　(61%) 20　(77%)
　0.5>　≥0.3 0   　　 1　 (3%) 2　(11%) 2 　(8%)
　0.3>　≥0 0   　　 0   　　 1　 (6%) 2 　(8%)
VA,  visual acuity;  VF-14,  visual function questionnare-14.
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Table 2　 Postoperative clinical ﬁndings
Comitant strabismus
n=51
Glaucoma
n=26
Unilateral cataract
n=21
Bilateral cataract
n=29
P
VA in better eye 0.4403
　Mean (SD), decimal 1.2　(0.3) 1.0　(0.4) 0.9　(0.4) 1.1　(0.4)
　Median 　 1.2 　 1.0 　 1.0 　 1.0
　≥1.0 46　(90%) 16　(62%) 13　(62%) 15　(52%)
　0.5≤　<1.0 4　 (8%) 8　(31%) 7　(33%) 9　(31%)
　<0.5 1　 (2%) 2　 (8%) 1　 (5%) 5　(17%)
VA in worse eye 0.1960
　Mean (SD), decimal 0.9　(0.4) 0.6　(0.5) 0.6　(0.4) 0.7　(0.4)
　Median 1.0  　　 0.5  　　 0.7  　　 0.7  　　
　≥1.0 31　(61%) 7　(27%) 6　(29%) 7　(24%)
　0.5≤　<1.0 10　(20%) 10　(38%) 11　(52%) 11　(38%)
　<0.5 10　(20%) 9　(35%) 4　(19%) 11　(38%)
VF-14 score 0.4252
　Mean (SD) 85.8 (14.8) 82.2 (17.3) 84.5 (11.0) 86.8 (15.1)
　Median 　88.6 　86.8 　83.9 　89.6
　100≥　≥80 35　(69%) 17　(65%) 13　(62%) 22　(76%)
　80>　≥40 16　(32%) 9　(35%) 8　(38%) 7　(24%)
　40>　≥0 0   　　 0   　　 0   　　 0   　　
Utility value 0.5986
　Mean (SD) 0.952　(0.07) 0.906 (0.140) 0.894 (0.228) 0.909 (0.155)
　1.0 21　(45%) 7　(27%) 7　(39%) 12　(46%)
　1.0>　≥0.5 26　(55%) 18　(69%) 10　(56%) 13　(50%)
　0.5>　≥0.3 0   　　 1 　(4%) 0   　　 0   　　
　0.3>　≥0 0   　　 0   　　 1 　(6%) 1 　(4%)
Utility gain 0.4666
　Mean 0.101 (0.105) 0.096 (0.105) 0.167 (0.237) 0.245 (0.167)
　1.0>　≥0.5 0   　　 0   　　 1 　(6%) 1 　(4%)
　0.5>　≥0.3 2 　(5%) 2 　(8%) 3　(17%) 8　(31%)
　0.3>　≥0.1 19　(40%) 7　(27%) 5　(28%) 13　(50%)
　0.1>　≥0 26　(55%) 17　(65%) 9　(50%) 4　(15%)
VA,  visual acuity;  VF-14,  visual function questionnare-14.
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Fig. 1　 Mean pre- and postoperative VF-14 scores in the 4 treat-
ment groups.
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Fig. 2　 Mean pre- and postoperative values of TTO utility in the 
4 treatment groups.
utility values and utility gain (postoperative utility 
value-preoperative utility value),  respectively.  The 
TTO utility value improved signiﬁcantly postopera-
tively in all 4 groups.  The mean (SD) of the utility 
gains was 0.096 (0.105) for glaucoma,  0.101 (0.105) 
for comitant strabismus,  0.167 (0.237) for unilateral 
and 0.245 (0.167) for bilateral cataract surgery,  and 
the utility gain was largest for bilateral cataract sur-
gery.  However,  the utility gain of bilateral cataract 
surgery was not double that of unilateral surgery,  
being only 46.7ｵ higher.  The numbers of patients who 
indicated an unwillingness to complete the TTO ques-
tionnaire survey before and after surgery and,  conse-
quently,  had a utility value of 0 were 25.5ｵ (12 
patients),  15.4ｵ (4),  22.2ｵ (4) and 7.7ｵ (2) in the 
comitant strabismus,  glaucoma,  and uni- and bilateral 
cataract surgery groups,  respectively,  being highest 
in the comitant strabismus and lowest in the bilateral 
cataract surgery group.  
　 Correlation between pre- and postoperative 
TTO utility value, VF-14 scores and other vari-
ables (Tables 3 and 4). Preoperatively,  no signiﬁ-
cant positive correlation was observed between the 
utility value and the VF-14 score in the 4 groups,  but 
postoperatively,  a signiﬁcant positive correlation was 
noted in the bilateral cataract surgery group 
(r=0.588,  p=0.002).  The preoperative utility value 
showed no signiﬁcant correlation with the corrected 
visual acuity of the better or worse eye of the 4 treat-
ment groups,  but the postoperative utility value 
showed a signiﬁcant negative correlation with the cor-
rected visual acuity of the better eye in the unilateral 
cataract group (r=－0.652,  p=0.003).  For the VF-14 
score,  a signiﬁcant correlation was observed with the 
preoperative visual acuity of the better eye in the 
comitant strabismus (r=－0.285,  p=0.04),  glaucoma 
(r=－0.440,  p=0.025) and bilateral cataract groups 
(r=－0.417,  p=0.024),  and with the postoperative 
visual acuity of the better eye in the glaucoma (r=－
0.480,  p=0.013) and bilateral cataract groups (r=－
0.406,  p=0.029).  Moreover,  the VF-14 score was 
signiﬁcantly correlated with the preoperative visual 
ﬁeld loss in the better (r=0.487,  p=0.008) and worse 
eye (r=0.423,  p=0.044) in the glaucoma group.  
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Table 3　 Relationship between preoperative utility value, VF-14 score, and other variables
Comitant strabismus
n=47
Utility value VA in better eye BSV Ocular deviation VA in worse eye
　VF-14 score 0.214 (0.150) －0.285* (0.04) 0.077 (0.607) 0.198 (0.163) 0.200 (0.147)
　Utility value 0.217 (0.144) 0.127 (0.424) －0.117 (0.431) －0.118 (0.435)
　VA in better eye 0.306* (0.048) －0.072 (0.616) 0.248 (0.080)
　BSV 0.171 (0.254) 0.344* (0.021)
　Ocular deviation 0.105 (0.465)
Glaucoma
n=26
Utility value VA in better eye VA in worse Eye VFL in better eye VFL in worse eye Medication score
　VF-14 score －0.046 (0.823) －0.440* (0.025) 0.315 (0.628) 0.487* (0.019) 0.423* (0.044) －0.017 (0.959)
　Utility value －0.158 (0.440) －0.205 (0.315) 0.232 (0.288) －0.057 (0.795) 0.412 (0.208)
　VA in better eye 0.388 (0.050) －0.536* (0.008) －0.311 (0.148) －0.182 (0.592)
　VFL in better eye 0.541* (<0.0001) 0.092 (0.813)
Unilateral cataract
n=18
Utility value VA in better eye VA in worse eye
　VF-14 score 0.012 (0.962) －0.157 (0.495) －0.395 (0.077)
　Utility value －0.241 (0.337) －0.267 (0.280)
　VA in better eye 0.477* (0.029)
Bilateral cataract
n=26
Utility value VA in better eye VA in worse eye
　VF-14 score 0.033 (0.874) －0.417* (0.024) 0.216 (0.261)
　Utility value －0.247 (0.223) 0.510 (0.806)
　VA in better eye 0.612* (0.0004)
VA,  visual acuity; BSV,  binocular single vision; VFL,  visual ﬁeld loss.
　 Relationships of the TTO utility value with 
visual acuity and other independent variables 
(Tables 5 and 6). Since the correlation coeﬃcient 
between the visual acuities of the better and worse 
eyes was moderately signiﬁcant pre- or postopera-
tively in the 4 groups,  the variables of the worse eye 
were excluded from the independent variables in the 
multiple regression analysis.  Similarly,  because there 
was a strong correlation between the MD values of the 
better and worse eyes in the glaucoma group,  the MD 
value of the worse eye was excluded from the vari-
ables of the multiple regression analysis.  
Preoperatively,  the coeﬃcient of determination in 
comitant strabismus was 0.4112 (p=0.0113).  The only 
independent variable that was signiﬁcant for comitant 
strabismus was being male.  Thus,  the utility value 
tended to be higher in males in the comitant strabis-
mus group.  Postoperatively,  the coeﬃcient of deter-
mination was 0.6045 (p=0.0408) in the bilateral cata-
ract surgery group.  The VF-14 score was a 
signiﬁcant independent variable in the bilateral cata-
ract surgery group.  Although the coeﬃcient of deter-
mination was not signiﬁcant (p=0.0584),  the corrected 
visual acuity of the better eye was a weak candidate 
independent variable in the unilateral cataract surgery 
group (p=0.0206).  Thus,  the TTO utility value 
tended to be higher as the VF-14 score was higher in 
the bilateral cataract surgery group,  and as corrected 
visual acuity of the better eye was better in the unilat-
eral cataract surgery group.  
　 Calculation of QALYs. Fig.  3 shows the 
mean (SD) of the QOLYs gained calculated by multi-
plying the utility value by the life expectancy and 
assuming annual discount rates of 3ｵ,  5ｵ,  and 
10ｵ.  The QALYs assuming an annual discount rate 
of 3ｵ was 0.870 (0.898) in glaucoma surgery,  1.132 
(1.148) in comitant strabismus,  and 1.424 (1.817) in 
unilateral and 2.181 (1.520) in bilateral cataract sur-
gery,  being highest for bilateral cataract surgery.  
However,  the mean of the QALYs gained by bilateral 
surgery was only 53ｵ higher than that by unilateral 
surgery.  
Discussion
　 Utility analysis was performed by measuring the 
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Table 4　 Relationship between postoperative utility value, VF-14 score, and other variables
Comitant strabismus
n=47
Utility value VA in better eye VA in worse eye BSV Ocular deviation Percent decrease 
in ocular deviation
　VF-14 score －0.202 (0.171) －0.352 (0.114) 0.105 (0.682) －0.086 (0.479) 0.056 (0.694) 0.186 (0.191)
　Utility value 0.049 (0.742) －0.041 (0.787) －0.159 (0.873) －0.082 (0.584) 0.081 (0.536)
　VA in better eye －0.053 (0.712) －0.113 (0.354) －0.125 (0.382) 0.075 (0.602)
　BSV 0.473* (0.0001) 0.432 (0.0004)
Glaucoma
n=26
Utility value VA in better eye VA in worse eye VFL VFL in worse eye Medication score
　VF-14 score 0.047 (0.817) －0.480* (0.013) －0.184 (0.366) 0.129 (0.719) 0.611 (0.061) －0.277 (0.410)
　Utility value 0.055 (0.793) －0.232 (0.255) 0.122 (0.706) 0.212 (0.532) －0.130 (0.704)
　VA in better eye 0.342 (0.087) －0.671* (0.017) －0.367 (0.263) －0.277 (0.426)
　VFL in better eye 0.564* (0.004) 0.314 (0.493)
Unilateral cata
ractn=18
Utility value VA in better eye VA in worse eye
　VF-14 score 0.145 (0.566) －0.303 (0.181) －0.338 (0.134)
　Utility value －0.652* (0.003) －0.148 (0.558)
　VA in better eye 0.351 (0.118)
Bilateral cataract
n=26
Utility value VA in better eye VA in worse eye
　VF-14 score 0.588* (0.002) －0.406* (0.029) －0.201 (0.295)
　Utility value －0.125 (0.542) －0.139 (0.498)
　VA in better eye 0.596* (0.006)
VA,  visual acuity; BSV,  binocular single vision; VFL,  visual ﬁeld loss.
pre- and postoperative utility values using the TTO 
method.  The preoperative utility value was highest at 
0.852 for comitant strabismus,  followed by 0.810 for 
glaucoma,  and 0.727 for unilateral and 0.663 for 
bilateral cataracts.  The TTO technique can also be 
used for comparisons with systemic diseases,  unlike 
assessment instruments of vision-related QOL such as 
the VF-14 [14] and VFQ-25 [19,  20].  When the 
results of the present study are compared with those 
of previous studies,  the utility value of comitant 
strabismus is between those of moderate angina pecto-
ris and myocardial infarction,  that of glaucoma is 
equivalent to that of moderate myocardial infarction,  
and that of cataracts is equivalent to moderate 
osteoarthritis of the hip [6,  16].
　 Since vision-related QOL measurement instru-
ments such as the VF-14 and VFQ-25 do not neces-
sarily correlate with TTO,  they are not usually used 
to analyze cost-eﬀectiveness or 
cost-utility [16].  However,  in 
the present study,  signiﬁcant 
correlations were observed 
between the postoperative TTO 
utility values and VF-14 scores in 
bilateral cataracts.  If there is a 
signiﬁcant relationship between 
the preoperative TTO utility 
value and VF-14 score,  the 
VF-14 can be utilized to analyze 
cost-eﬀectiveness.  The TTO 
method is also applicable to QOL 
measurement in cataracts such as 
dry eye [26].
　 The corrected visual acuity of 
the better eye has been reported 
as an important factor related to 
TTO [3,  6,  11,  16,  27,  28].  
In the present study,  signiﬁcant 
correlations were also noted 
between the utility value and cor-
rected visual acuity of the better 
eye of the postoperative unilat-
eral cataract.  Signiﬁcant corre-
lations were noted between the 
VF-14 score and corrected visual 
acuity of the better eye in the 
pre- and postoperative glaucoma 
and bilateral cataract groups.  
The TTO utility value is considered to accurately 
reﬂect the state of activities of daily living aﬀected by 
visual impairment similarly to the VF-14 score,  and 
TTO can be regarded as a suitable method for direct 
measurement of the utility value.
　 The TTO utility value improved signiﬁcantly com-
pared with that before surgery in all 4 treatment 
groups.  In the present study,  the utility gain was 
largest in cataract surgery and was larger in bilateral 
than unilateral surgery.  In Japan,  a utility analysis of 
bilateral cataract surgery using TTO was reported by 
Senba [28],  who observed a utility gain close to that 
in the present study (0.226 reported by Senba vs.  
0.245 in the present study).  The utility analyses of 
cataract surgery to date have revealed 2 characteris-
tics.  One is that the utility gain diﬀers between 
developed and developing countries,  with the gain 
being smaller in developed countries (0.159 vs.  0.190) 
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Table 5　 Multiple regression analysis with the preoperative utility value as a dependent 
variable
Partial correlation coeﬃcient P-value
Comitant strabismus　(n=47)
　Age －0.0008 0.7144
　Gender －0.0480 0.0068*
　VF-14 score 　0.0016 0.0865
　Type －0.0920 0.1751
　Visual acuity in better eye 　0.2084 0.1281
　Preoperative deviation －0.0008 0.4196
　Preoperative binocular vision 　0.0262 0.3699
　Coeﬃcient of determination (p-value) 0.6567 (0.0236)
Glaucoma　(n=26)
　Age －0.0053 0.1040
　Gender 　0.0759 0.0485
　VF-14 score －0.0031 0.2075
　Visual acuity in better eye －0.2748 0.3105
　Visual ﬁeld loss in better eye 　0.0076 0.2687
　Coeﬃcient of determination (p-value) 0.5961 (0.1521)
Unilateral cataract　(n=18)
　Age －0.0127 0.1436
　Gender 　0.0196 0.7916
　VF-14 score 　0.0032 0.5906
　Visual acuity in better eye 　0.0412 0.8644
　Coeﬃcient of determination (p-value) 0.2288 (0.4595)
Bilateral cataract　(n=26)
　Age －0.0100  0.1647
　Gender －0.0023 0.9564
　VF-14 score －0.0015 0.4904
　Visual acuity in better eye －0.2055 0.1559
　Coeﬃcient of determination (p-value) 0.1574 (0.4390)
[29].  The other is that the util-
ity gain is greater in the ﬁrst than 
the second surgery (0.148 vs.  
0.109) [30,  31].  If the unilat-
eral surgery in the present study 
is assumed to be the ﬁrst sur-
gery,  the utility gain (0.167) is 
close to that in developed coun-
tries.  Also,  if the diﬀerence in 
the utility gain between bilateral 
and unilateral surgery is assumed 
to be the utility gain of the second 
surgery,  it is calculated as 0.078 
in this study,  similar to the pre-
vious study,  and is smaller than 
that in the ﬁrst surgery.  Thus,  
the eﬀect of unilateral surgery on 
the vision-related QOL is consid-
ered to be extremely large.  
　 The utility gain following 
strabismus surgery in adults 
analyzed using TTO was greater 
in the previous (0.1175) [25,  32] 
than in the present (0.101) study.  
The reasons are as follows.  In 
contrast to our study,  the previ-
ous study analyzed the utility gain 
without diﬀerentiating comitant 
from incomitant strabismus.  
Diplopia encountered in cases of 
incomitant strabismus could inﬂuence daily QOL.  
Therefore,  dissolution of diplopia by surgery could 
greatly increase the utility value.  On the other hand,  
compared to our results,  the mean utility value of the 
Japanese multicenter study of comitant strabismus was 
lower [0.101 (0.105) for our study vs.  0.06 (0.16) for 
the multi-center study] [33].  This diﬀerence could be 
attributable to the large distribution of surgical 
results among facilities participating in this study.
　 There has been no study on the utility analysis of 
glaucoma surgery using TTO other than this one.  The 
present study revealed characteristics of utility analy-
sis.  The utility gain in glaucoma was almost equal to 
that in comitant strabismus,  although the visual acu-
ity,  as well as the visual ﬁeld loss,  remained 
unchanged postoperatively.  One reason for this ﬁnding 
was that the proportion of patients who stopped using 
either eye drops or internal medicine increased from 
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Table 6　 Multiple regression analysis with the postoperative utility value as a dependent 
variable
Partial correlation coeﬃcient P-value
Comitant strabismus　(n=47)
　Age 　0.0003 0.8330
　Gender －0.0190 0.0748
　VF-14 score －0.0006 0.4533
　Type －0.0267 0.8311
　Visual acuity in better eye －0.0143 0.9092
　Preoperative deviation －0.0002 0.8990
　Preoperative binocular vision 0.0060 0.6840
　Coeﬃcient of determination (p-value) 0.4214 (0.7412)
Glaucoma　(n=26)
　Age －0.0059 0.3517
　Gender 　0.0316 0.6505
　VF-14 score －0.0126 0.1718
　Visual acuity in better eye 　0.0890 0.8075
　Visual ﬁeld loss in better eye 　0.0210 0.1812
　Coeﬃcient of determination (p-value) 0.4827 (0.4393)
Unilateral cataract　(n=18)
　Age 　0.0012 0.8088
　Gender 　0.0545 0.3251
　VF-14 score －0.0007 0.9030
　Visual acuity in better eye －0.6538 0.0206
　Coeﬃcient of determination (p-value) 0.4805 (0.0584)
Bilateral cataract　(n=26)
　Age －0.0004 0.9393
　Gender －0.0027 0.9243
　VF-14 score 　0.0063  0.0152*
　Visual acuity in better eye 　0.0842 0.4616
　Coeﬃcient of determination (p-value) 0.604 (0.0408)
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Fig. 3　 Mean QALYs for the 4 treatment groups calculated with 
annual discount rates of 3%, 5%, and 10%.
0ｵ to 36.4ｵ postoperatively.  Second,  the glaucoma 
operation has a psychological eﬀect in that fear of 
blindness can be reduced.
　 Multiple regression analysis revealed the charac-
teristics of each disease.  Preoperatively,  the utility 
value was high in males in the comitant strabismus 
group.  Postoperatively,  the utility value was corre-
lated with the VF-14 score in the bilateral cataract 
group.  Visual ﬁeld loss,  which is an important symp-
tom of glaucoma,  showed no correlation with the 
VF-14 or TTO score on simple linear or multiple 
regression analysis.  This ﬁnding supports the results 
reported by Gupta [34].  There are,  however,  
reports showing correlations [35,  36],  and the rela-
tionship between visual ﬁeld loss and TTO remains 
controversial.  
　 The mean of the QALYs gained by surgical treat-
ment was 1.0 or greater in all 3 surgical intervention 
groups evaluated in this study (Fig.  3).  Concerning 
the individual groups,  the mean of the QALYs gained 
was large in the strabismus group,  with the exception 
of the patients with cataracts.  This is considered to 
have been due to the improvement in the QOL and 
resultant improvement in the TTO score.  For patients 
with strabismus,  the socioeconomic disadvantages and 
psychological eﬀects have come to be perceived as 
problems [32].  In Japan,  there has been a multi-
center analysis of the eﬀect of strabismus surgery on 
QOL using the NEI VFQ-25 and a report on the 
eﬀectiveness of strabismus surgery on QOL [33].
　 There were several limitations in the present 
study.  The ﬁrst is that the study was retrospective.  
This is considered to be the reason why a signiﬁcant 
correlation could not be demonstrated preoperatively 
between the TTO and VF-14 score or corrected visual 
acuity in the 3 diseases,  although these correlations 
were suggested by a previous study [28].  The second 
is the possibility of bias in the results because the 
subjects were limited to those at our clinic,  rather 
than multiple facilities.  However,  no marked diﬀer-
ence was noted compared with the results of previous 
studies concerning strabismus [32] or cataract sur-
gery [28-31].  Therefore,  the bias is likely to have 
been negligible.  The third is related to comorbidities.  
However,  as the utility value is generally considered 
not to be aﬀected by comorbidities other than the 
primary disease [37],  utility values related to comor-
bidities were not analyzed in this study.  The fourth is 
the lasting eﬀect of surgical intervention.  Calculation 
of QALYs is based on the assumption that the eﬀect 
of surgical intervention lasts for the whole lifetime.  
This may be true in the case of cataract surgery and 
in some patients with adult comitant strabismus [38,  
39].  However,  it is apparent that some patients with 
strabismus or glaucoma require additional surgery in 
the future.  For these reasons,  the QALYs gain was 
calculated with assumed annual discount rates of 3ｵ,  
5ｵ,  and 10ｵ,  respectively.  The ﬁfth  is the number 
of patients undergoing TTO utility analysis was 
smaller than the number undergoing VF-14 analysis.  
Therefore,  TTO utility analysis may not accurately 
represent the characteristics of all patients.
　 In conclusion,  both the TTO and VF-14 score are 
related to the postoperative visual acuity of the better 
eye in unilateral cataracts,  and the VF-14 score to 
that in bilateral cataracts; the utility values are thus 
considered to be valid for use in cataract surgery.  
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